More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials
- PMID: 2182437
- DOI: 10.1007/978-3-642-74643-7_83
More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials
Abstract
Between 1973 and 1985, 553 children with childhood acute lymphoblastic leukemia were treated on Dana-Farber Cancer Institute/Children's Hospital, Boston, protocols. The programs featured intensive remission induction therapy, CNS treatment with cranial irradiation and intrathecal drugs, doxorubicin intensification with or without asparaginase, and 2-21/2 years of conventional continuation therapy. There has been progressive improvement in event-free survival for each successive program. Leukemia control concerns pertain to: 1. late relapses (at greater than 5 years) in "standard-risk" patients; 2. an increased incidence of CNS relapses, especially in "standard-risk" patients, as preventative treatment is reduced in intensity; and 3. bone marrow relapses in "high-risk"patients. Comparisons of patients receiving the more intensive arm of each protocol with those receiving the less intensive arm support the hypothesis that more intensive chemotherapy results in improved event-free survival.
Similar articles
-
Results of acute lymphoblastic leukemia therapy in childhood: GDR-experiences 1981-1987.Haematol Blood Transfus. 1990;33:478-82. doi: 10.1007/978-3-642-74643-7_86. Haematol Blood Transfus. 1990. PMID: 2182440 Clinical Trial. No abstract available.
-
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.J Clin Oncol. 1995 Oct;13(10):2497-502. doi: 10.1200/JCO.1995.13.10.2497. J Clin Oncol. 1995. PMID: 7595699 Clinical Trial.
-
Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.CMAJ. 1989 Oct 1;141(7):693-7. CMAJ. 1989. PMID: 2790605 Free PMC article.
-
Results and significance of six randomized trials in four consecutive ALL-BFM studies.Haematol Blood Transfus. 1990;33:439-50. doi: 10.1007/978-3-642-74643-7_81. Haematol Blood Transfus. 1990. PMID: 2182435 Review. No abstract available.
-
Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials.Haematol Blood Transfus. 1990;33:500-3. doi: 10.1007/978-3-642-74643-7_90. Haematol Blood Transfus. 1990. PMID: 2182444 Review.
Cited by
-
Asparaginase-associated pancreatitis in chemotherapy-treated pediatric patients: a five-year retrospective study.World J Emerg Med. 2022;13(4):313-321. doi: 10.5847/wjem.j.1920-8642.2022.062. World J Emerg Med. 2022. PMID: 35837564 Free PMC article. No abstract available.
-
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?Haematologica. 2022 Feb 1;107(2):356-357. doi: 10.3324/haematol.2021.279059. Haematologica. 2022. PMID: 34196170 Free PMC article. No abstract available.
-
Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study.Front Oncol. 2020 Oct 28;10:538779. doi: 10.3389/fonc.2020.538779. eCollection 2020. Front Oncol. 2020. Retraction in: Front Oncol. 2021 Jun 03;11:709636. doi: 10.3389/fonc.2021.709636. PMID: 33194600 Free PMC article. Retracted.
-
National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?BMC Cancer. 2020 Oct 2;20(1):956. doi: 10.1186/s12885-020-07461-5. BMC Cancer. 2020. PMID: 33008391 Free PMC article.
-
Asparaginase: an old drug with new questions.Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):275-282. doi: 10.1016/j.htct.2019.07.010. Epub 2019 Oct 18. Hematol Transfus Cell Ther. 2020. PMID: 31801703 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Miscellaneous